Alzamend Neuro, Inc. (ALZN) analyst actions
Rating and price-target actions on ALZN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALZN overview →
7 measured ALZN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital | Press release | +0.00% | -7.89% | |
| Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital | Press release | -5.88% | -31.70% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital | Press release | -7.08% | -10.62% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital | Press release | -5.56% | +4.43% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital | Press release | +0.00% | -2.45% | |
| Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital | Press release | +0.00% | -1.50% | |
| Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital | Press release | +0.26% | -2.07% |
Keep exploring
More ALZN: earnings → · SEC filings → · ALZN overview →